Background: Although inotropic stimulation is considered harmful in the presence of myocardial ischaemia, both calcium sensitisers and phosphodiesterase inhibitors may offer cardioprotection. We hypothesise that these cardioprotective effects are related to an acute alteration of myocardial metabolism. We studied in vivo effects of milrinone and levosimendan on calcium overload and ischaemic markers using left ventricular microdialysis in pigs with acute myocardial ischaemia.

Methods: Anaesthetised juvenile pigs, average weight 36 kg, were randomised to one of three intravenous treatment groups: milrinone 50 μg/kg bolus plus infusion 0.5 μg/kg/min (n = 7), levosimendan 24 μg/kg plus infusion 0.2 μg/kg/min (n = 7), or placebo (n = 6) for 60 min prior to and during a 45 min acute regional coronary occlusion. Systemic and myocardial haemodynamics were assessed, and microdialysis was performed with catheters positioned in the left ventricular wall. (45) Ca(2+) was included in the microperfusate in order to assess local calcium uptake into myocardial cells. The microdialysate was analysed for glucose, lactate, pyruvate, glycerol, and for (45) Ca(2+) recovery.

Results: During ischaemia, there were no differences in microdialysate-measured parameters between control animals and milrinone- or levosimendan-treated groups. In the pre-ischaemic period, arterial blood pressure decreased in all groups while myocardial oxygen consumption remained stable.

Conclusions: These findings reject the hypothesis of an immediate energy-conserving effect of milrinone and levosimendan during acute myocardial ischaemia. On the other hand, the data show that inotropic support with milrinone and levosimendan does not worsen the metabolic parameters that were measured in the ischaemic myocardium.

Download full-text PDF

Source
http://dx.doi.org/10.1111/aas.12095DOI Listing

Publication Analysis

Top Keywords

milrinone levosimendan
16
myocardial
8
calcium overload
8
myocardial ischaemia
8
left ventricular
8
acute myocardial
8
infusion μg/kg/min
8
milrinone
5
levosimendan porcine
4
porcine myocardial
4

Similar Publications

Background: As the burden of cardiovascular disease grows, so does the number of cardiac surgeries. Surgery is increasingly performed on older people with comorbidities who are at higher risk of developing perioperative complications such as low cardiac output state (LCOS). Surgery-associated LCOS represents a serious pathology responsible for substantial morbidity and mortality.

View Article and Find Full Text PDF

Inotropes for the prevention of low cardiac output syndrome and mortality for paediatric patients undergoing surgery for congenital heart disease: a network meta-analysis.

Cochrane Database Syst Rev

November 2024

Department of Congenital Heart Disease and Pediatric Cardiology, University Heart Center, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Background: Paediatric patients undergoing surgery for congenital heart disease (CHD) are at risk for postoperative low cardiac output syndrome (LCOS) and mortality. LCOS affects up to 25% of children after heart surgery. It consists of reduced myocardial function and increases postoperative morbidity, prolongs mechanical ventilation, and lengthens the duration of intensive care unit (ICU) stay.

View Article and Find Full Text PDF

Hemodynamic management of acute kidney injury.

Curr Opin Crit Care

December 2024

Department of Anesthesiology, Intensive Care & Perioperative Medicine, Assistance Publique Hôpitaux de Paris. Paris Saclay University, Paris, France.

Purpose Of Review: To discuss the role of hemodynamic management in critically ill patients with acute kidney injury.

Recent Findings: Acute kidney injury (AKI) may be associated with persistent alterations in renal perfusion, even when cardiac output and blood pressure are preserved. The effects of interventions aiming at increasing renal perfusion are best evaluated by renal Doppler or contrast enhance ultrasound.

View Article and Find Full Text PDF

Discovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.

Hum Exp Toxicol

October 2024

Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran.

Article Synopsis
  • Aluminum phosphide (AlP) is a dangerous chemical that can cause death by harming heart cells, and there aren't any approved medicines to treat it yet.
  • Researchers are looking into different ways to lessen the harmful effects of AlP poisoning, including improving heart function and using various compounds.
  • Some treatments like fresh red blood cell transfusion and certain medicines show promise in helping patients, but more research is needed to confirm the best ways to treat AlP poisoning.
View Article and Find Full Text PDF

The perioperative management of patients with pulmonary hypertension (PH) undergoing cardiac surgery is challenging, mainly due to the potential risk of right ventricular failure (RVF). Levosimendan is a calcium-sensitizing agent that has primarily been used in the treatment of decompensated heart failure. However, recently levosimendan has been shown to be an effective and safe therapeutic strategy for patients with pulmonary arterial hypertension and PH associated with left heart disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!